Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19232073 | 0.96 | TSHR (0.49) | TSHRHSD17B10CYP19A1NR1I2CYP2A6 | |
| SCHEMBL22664881 | 0.95 | TSHR (0.51) | TSHRHSD17B10CYP19A1NR1I2CYP2A6 | |
| SCHEMBL8131540 | 0.93 | TSHR (0.50) | TSHRHSD17B10CYP19A1NR1I2CYP2A6 | |
| SCHEMBL18432620 | 0.91 | CYP2A6 (0.48) | TSHRHSD17B10CYP19A1CYP2A6SLC6A3 | |
| SCHEMBL19389267 | 0.88 | NR1I2 (0.55) | TSHRHSD17B10CYP19A1NR1I2CYP2A6 | |
| SCHEMBL20011777 | 0.84 | NR1I2 (0.46) | TSHRHSD17B10CYP19A1NR1I2CYP2A6 | |
| SCHEMBL14162362 | 0.84 | CYP2A6 (0.45) | TSHRHSD17B10CYP19A1NR1I2CYP2A6 | |
| SCHEMBL19525845 | 0.83 | TSHR (0.41) | TSHRHSD17B10CYP19A1NR1I2CYP2A6 | |
| SCHEMBL25334238 | 0.82 | TSHR (0.43) | TSHRHSD17B10CYP19A1NR1I2CYP2A6 | |
| SCHEMBL19464663 | 0.79 | TSHR (0.50) | TSHRHSD17B10CYP19A1CYP2A6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253525-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200069695-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253525-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | TSHR 3875/4885HSD17B10 1463/4885CYP19A1 588/4885 |
| US-20200069695-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | TSHR 3875/4885HSD17B10 1463/4885CYP19A1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.